Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials.

Wolfgang KoenigLorena Garcia CondeUlf LandmesserLawrence A LeiterKausik K RayGregory G SchwartzR Scott WrightJackie HanFrederick J Raal

Published in: Cardiovascular drugs and therapy (2022)

Twice-yearly inclisiran dosing (after the initial and 3-month doses) was well tolerated and provided effective and sustained lipid-lowering in patients, irrespective of PVD status.

Keyphrases

end stage renal disease
randomized controlled trial
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
systematic review
fatty acid